Product Information
- 4-[6-Hydroxy-3-[4-[2-(1-piperindinyl)ethoxy]benzoyl]benzo[b]thien-2-yl]phenyl-β-D-glucopyranosiduronic acid
- (4-[6-Hydroxy-3-[4-[2-(1-piperidinyl)ethoxy-D4]benzoyl]benzo[b]thien-2-yl]phenyl-D-glucopyranosiduronic acid)
- 4-[6-Hydroxy-3-[4-[2-(1-piperidinyl)ethoxy-d4]benzoyl]benzo[b]thien-2-yl]phenyl-b-D-glucopyranosiduronic Acid
- 4-[6-Hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]benzoyl]benzo[b]thien-2-yl]phenyl β-<span class="text-smallcaps">D</span>-glucopyranosiduronic acid
- 4-[6-Hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]benzoyl]benzo[b]thien-2-yl]phenyl-D-glucopyranosiduronicacid
- 4-[6-Hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]benzoyl]benzo[b]thien-2-yl]phenyl-b-D-glucopyranosiduronic Acid
- Raloxifene-D4-4'-Glucuronide
- β-<span class="text-smallcaps">D</span>-Glucopyranosiduronic acid, 4-[6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]benzoyl]benzo[b]thien-2-yl]phenyl
Raloxifene 4'-D-glucuronide is a drug that is a prodrug of raloxifene, and it can be used to treat osteoporosis. The compound is metabolized by glucuronidation in the liver, and it has been found to have bioequivalence with the parent drug. Raloxifene 4'-D-glucuronide is marketed under the trade name Evista.
Raloxifene 4'-D-glucuronide is a prodrug of raloxifene, which can be used to treat osteoporosis. This compound has been found to have bioequivalence with the parent drug and is marketed under the trade name Evista.
Chemical properties
Technical inquiry about: 3D-MR07277 Raloxifene 4'-D-glucuronide
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
